Baker Bros. Advisors LP Kymera Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 5,995,928 shares of KYMR stock, worth $272 Million. This represents 2.38% of its overall portfolio holdings.
Number of Shares
5,995,928
Previous 5,995,928
-0.0%
Holding current value
$272 Million
Previous $241 Million
25.75%
% of portfolio
2.38%
Previous 3.05%
Shares
6 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$290 Million0.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$243 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$234 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$219 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.31MShares$196 Million0.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.48B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...